1. Home
  2. Shareholder and Investor Information
  3. Understanding RaQualia Pharma! RaQualia FAQ
  4. What are RaQualia’s strengths?

Shareholder and Investor Information

What are RaQualia's strengths?

  1. 1. A company that has its own strengths

    Human resources
    A group of researchers with broad experiences and a solid record of achievements in developing medications
    A management team that understands the needs of global customers
    Portfolio
    Consistent creation of new development compounds
    Expansion of market potential by adding new target indications
    Improvement of the probability of commercialization by rapid confirmation of product concepts
    Infrastructure
    A comprehensive research support structure and the most advanced research facility
    Growth Potential
    The ability to produce one new development compounds per year
  2. 2. Open Collaboration Based on Trust

    The foundation of RaQualia Pharma's business model is the Integrated Open Collaboration Network (IOCN). IOCN does not distinguish between external and internal company resources. All employees focus on innovation and, by cooperating with partners both inside and outside the company, make high and sustained productivity possible. RaQualia Pharma's core competence is to rapidly, efficiently, and effectively create research programs and development candidate compounds. We actively seek opportunities for partnership via licensing and joint development in all of these programs and at all research stages. This model is the driving force behind improving value for patients, our customers, investors and shareholders.

    IOCN is based on trust with our partners. Building trust among our colleagues, in other words both within RaQualia and between RaQualia and companies, customers, partners and stakeholders, is the foundation.

  • Previous
  • Next
  • FAQ

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics